Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP,Chief Info&Digital Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,716.037 |
Ending reported balance
After 2026-08-05 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-05 · Exercise / conversion · Acquired 4,600 · Balance 36,316.037 Row 2 · 2026-08-05 · Sale · Disposed 4,600 · Balance 31,716.037 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 3 · 2026-08-05 · Exercise / conversion · Acquired 13,542 · Balance 45,258.037 Row 4 · 2026-08-05 · Sale · Disposed 13,542 · Balance 31,716.037 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 5 · 2026-08-05 · Exercise / conversion · Acquired 34,705 · Balance 66,421.037 Row 6 · 2026-08-05 · Sale · Disposed 34,705 · Balance 31,716.037 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.62 · Expires 2029-05-02 | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-05 · Exercise / conversion · Disposed 4,600 · Balance 0 F2: The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.36 · Expires 2030-04-30 | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-05 · Exercise / conversion · Disposed 13,542 · Balance 0 F3: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.73 · Expires 2031-05-03 | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-05 · Exercise / conversion · Disposed 34,705 · Balance 0 F3: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022.
F3: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
F4: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
F5: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,705 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · derivative · entry 9 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,705 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,542 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · derivative · entry 8 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,542 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $77.62 | $0.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · derivative · entry 7 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,600 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 34,705 | $128.77 | $4,468,987.14 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 6 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 34,705 | $73.73 | $2,558,799.65 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 5 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,421.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 13,542 | $128.77 | $1,743,812.82 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 4 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 13,542 | $75.36 | $1,020,525.12 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,258.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 4,600 | $128.77 | $592,345.22 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,600 | $77.62 | $357,052.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,316.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 13,582 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000137 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,582 Underlying: Common Stock · 13,582 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 16:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000137 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,640 Underlying: Common Stock · 4,640 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000092 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,755 Underlying: Common Stock · 1,377 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 679 | $110.03 | $74,710.37 |
DisclosureSEC source: 0000310158-26-000092 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,377 | $110.03 | $151,511.31 |
DisclosureSEC source: 0000310158-26-000092 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,395.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $77.62 | $0.00 |
DisclosureSEC source: 0000310158-26-000044 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 5,000 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 5,000 | $121.91 | $609,525.00 |
DisclosureSEC source: 0000310158-26-000044 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,837.743 Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,000 | $77.62 | $388,100.00 |
DisclosureSEC source: 0000310158-26-000044 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,837.743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 6,112 | $107.40 | $656,428.80 |
DisclosureSEC source: 0000310158-26-000026 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,837.743 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 8,614 | $83.59 | $720,039.95 |
DisclosureSEC source: 0000310158-25-000056 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,578.031 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.5400 to $83.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 12:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 17,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-25-000012 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,119 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in one installment on 8/4/2025, the business day immediately following 8/3/2025. The Reporting Person's Form 4 filed on 8/4/2022 incorrectly reported that these restricted stock units vested and were to be distributed in three equal installments on 8/3/2023, 8/3/2024, and 8/3/2025. F3 · derivative.expiration_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in one installment on 8/4/2025, the business day immediately following 8/3/2025. The Reporting Person's Form 4 filed on 8/4/2022 incorrectly reported that these restricted stock units vested and were to be distributed in three equal installments on 8/3/2023, 8/3/2024, and 8/3/2025. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 12:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 8,432 | $79.29 | $668,573.28 |
DisclosureSEC source: 0000310158-25-000012 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,013.467 Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 12:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 17,119 | $79.29 | $1,357,365.51 |
DisclosureSEC source: 0000310158-25-000012 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,445.467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 18,807 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013053 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,807 Underlying: Common Stock · 18,807 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013053 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,132 Underlying: Common Stock · 4,132 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 6,000 | $85.34 | $512,056.80 |
DisclosureSEC source: 0001127602-25-004615 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,123.316 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 10,246 | $97.94 | $1,003,493.24 |
DisclosureSEC source: 0001127602-25-002355 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,123.316 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 16,406 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013937 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,406 Underlying: Common Stock · 16,406 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 1,451 | $127.57 | $185,108.28 |
DisclosureSEC source: 0001127602-24-003969 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,811.667 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 10,196 | $119.43 | $1,217,708.28 |
DisclosureSEC source: 0001127602-24-002032 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,262.667 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,035 | $0.00 Strike: $56.04 | $0.00 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · derivative · entry 6 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,035 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 7,509 | $116.82 | $877,222.41 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 4 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,058.96 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.7200 to $116.8800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,035 | $56.04 | $338,201.40 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,567.96 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:22 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 19,364 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014569 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,364 Underlying: Common Stock · 19,364 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · derivative · entry 5 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 577 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 198 | $115.47 | $22,863.06 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,532.96 Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 577 | $115.47 | $66,626.19 |
DisclosureSEC source: 0001127602-23-014278 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,730.96 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004855 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,205 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 413 | $106.72 | $44,075.36 |
DisclosureSEC source: 0001127602-23-004855 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,091.892 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,205 | $106.72 | $128,597.60 |
DisclosureSEC source: 0001127602-23-004855 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,504.892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 1,745 | $109.88 | $191,740.60 |
DisclosureSEC source: 0001127602-23-002251 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,007.757 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 19:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 17,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020468 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,119 Underlying: Common Stock · 17,119 shares Expires 2025-08-03 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 427 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013267 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 427 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 147 | $87.65 | $12,884.55 |
DisclosureSEC source: 0001127602-22-013267 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,262.757 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 427 | $87.65 | $37,426.55 |
DisclosureSEC source: 0001127602-22-013267 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,409.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 21,359 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013539 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Underlying: Common Stock · 21,359 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013026 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577 Underlying: Common Stock · 577 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 198 | $88.69 | $17,560.62 |
DisclosureSEC source: 0001127602-22-013026 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,982.757 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 577 | $88.69 | $51,174.13 |
DisclosureSEC source: 0001127602-22-013026 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,180.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 1,660 | $73.51 | $122,026.60 |
DisclosureSEC source: 0001127602-22-007028 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,603.757 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 16:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004674 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205 Underlying: Common Stock · 1,202 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023. F3 · derivative.underlying_shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.